Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) Receives Consensus Rating of "Moderate Buy" from Analysts

Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD - Get Free Report) has been given an average recommendation of "Moderate Buy" by the seven research firms that are presently covering the stock, Marketbeat Ratings reports. Three research analysts have rated the stock with a hold rating and four have issued a buy rating on the company. The average 1 year price target among brokerages that have issued a report on the stock in the last year is $12.17.

Several research analysts have issued reports on IRWD shares. Wells Fargo & Company decreased their price target on shares of Ironwood Pharmaceuticals from $14.00 to $12.00 and set an "overweight" rating on the stock in a research report on Friday, August 9th. Leerink Partners started coverage on shares of Ironwood Pharmaceuticals in a research report on Monday, September 9th. They issued a "market perform" rating and a $5.00 price target on the stock. Craig Hallum decreased their price target on shares of Ironwood Pharmaceuticals from $14.00 to $10.00 and set a "buy" rating on the stock in a research report on Friday, August 9th. Leerink Partnrs upgraded shares of Ironwood Pharmaceuticals to a "hold" rating in a research report on Monday, September 9th. Finally, Capital One Financial lowered shares of Ironwood Pharmaceuticals from an "overweight" rating to an "equal weight" rating and decreased their price objective for the stock from $12.00 to $4.00 in a research note on Thursday, August 8th.

Ironwood Pharmaceuticals Price Performance

Shares of NASDAQ IRWD traded down $0.04 during mid-day trading on Friday, reaching $4.40. 905,784 shares of the company traded hands, compared to its average volume of 3,064,327. The firm has a market cap of $688.73 million, a PE ratio of -0.65 and a beta of 0.48. Ironwood Pharmaceuticals has a fifty-two week low of $3.79 and a fifty-two week high of $15.70. The stock has a fifty day simple moving average of $4.46 and a 200-day simple moving average of $6.00.

Insider Buying and Selling at Ironwood Pharmaceuticals

In other Ironwood Pharmaceuticals news, insider Minardo John sold 9,910 shares of Ironwood Pharmaceuticals stock in a transaction on Monday, August 12th. The shares were sold at an average price of $4.27, for a total transaction of $42,315.70. Following the completion of the sale, the insider now owns 284,661 shares of the company's stock, valued at $1,215,502.47. This trade represents a 0.00 % decrease in their position. The sale was disclosed in a filing with the SEC, which is available at this hyperlink. Company insiders own 12.90% of the company's stock.

Institutional Investors Weigh In On Ironwood Pharmaceuticals

Several institutional investors and hedge funds have recently modified their holdings of the business. PNC Financial Services Group Inc. raised its holdings in Ironwood Pharmaceuticals by 152.2% in the 4th quarter. PNC Financial Services Group Inc. now owns 4,383 shares of the biotechnology company's stock worth $50,000 after acquiring an additional 2,645 shares during the period. CWM LLC lifted its position in shares of Ironwood Pharmaceuticals by 55.1% during the second quarter. CWM LLC now owns 6,600 shares of the biotechnology company's stock worth $43,000 after purchasing an additional 2,345 shares in the last quarter. SG Americas Securities LLC acquired a new position in shares of Ironwood Pharmaceuticals during the first quarter worth approximately $91,000. GAMMA Investing LLC raised its stake in shares of Ironwood Pharmaceuticals by 344.1% during the second quarter. GAMMA Investing LLC now owns 10,526 shares of the biotechnology company's stock worth $69,000 after buying an additional 8,156 shares during the last quarter. Finally, EntryPoint Capital LLC raised its stake in shares of Ironwood Pharmaceuticals by 517.4% during the first quarter. EntryPoint Capital LLC now owns 10,589 shares of the biotechnology company's stock worth $92,000 after buying an additional 8,874 shares during the last quarter.

About Ironwood Pharmaceuticals

Ironwood Pharmaceuticals, Inc, a healthcare company, focuses on the development and commercialization of gastrointestinal (GI) products. It markets linaclotide, a guanylate cyclase type-C (GC-C) agonist for the treatment of adults suffering from irritable bowel syndrome with constipation or chronic idiopathic constipation under the LINZESS name in the United States, Mexico, Japan, Saudi Arabia, and China, as well as under the CONSTELLA name in the Canada and European countries.